Art. -Nr.: HY-10046

Plerixafor

Name: Plerixafor
Brand: MedChemExpress
SKU: HY-10046
Price: 54.00 USD
Availability: InStock
Rating: 5 (120 reviews)

(Synonyms: AMD 3100; JM3100; SID791)

120 Cited Publications

Kundenbewertung

Based on 120 publication(s) in Google Scholar

Plerixafor (AMD 3100; JM3100; SID791) is a CXCR4 antagonist and a CXCR7 allosteric agonist; Plerixafor disrupts stem cell retention in the bone marrow by blocking the SDF-1α/CXCL12‑CXCR4 signaling pathway and inhibiting chemokine-mediated receptor internalization, mobilizing peripheral blood leukocytes, neutrophils, endothelial progenitor cells, and B cells; Plerixafor alleviates Silicon dioxide (HY-W019831)-induced pulmonary inflammation and fibrosis, inhibits corneal neovascularization and CXCL12-induced cell migration, and simultaneously suppresses ischemia-induced inflammatory responses, reduces blood-brain barrier permeability, attenuates cerebral edema, and reduces infarct volume. Plerixafor can be used in research related to liver fibrosis, silicosis, colorectal cancer, and ischemic stroke.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.92%
CAS. Nr.: 110078-46-1
Formel: C₂₈H₅₄N₈
Molecular Weight:502.78

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Plerixafor Chemical Structure

CAS. Nr.: 110078-46-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (120)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[3]^[11]

CXCR4

CXCR7

Alle CXCR Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
CCRF-CEM	IC₅₀	245 nM Compound: AMD-3100	Displacement of [125I]CXCL12 from CXCR4 in human CEM cells Displacement of [125I]CXCL12 from CXCR4 in human CEM cells	[PMID: 19053768]
CEM-SS	CC₅₀	>10 μM Compound: AMD-3100	Concentration of compound causing 50% death of uninfected cells Concentration of compound causing 50% death of uninfected cells	[PMID: 14698189]
CEM-SS	CC₅₀	>5 μM Compound: AMD-3100	Cytotoxicity against human CEM-SS cells by MTT assay Cytotoxicity against human CEM-SS cells by MTT assay	[PMID: 19356827]
CEM-SS	EC₅₀	0.127 μM Compound: AMD-3100	Effective concentration of compound against HIV-1 LAI strain in CEM-SS cells Effective concentration of compound against HIV-1 LAI strain in CEM-SS cells	[PMID: 14698189]
CEM-SS	IC₅₀	0.32 μM Compound: AMD-3100	Antiviral activity against HIV1 LAI in human CEM-SS cells assessed as inhibition of viral replication Antiviral activity against HIV1 LAI in human CEM-SS cells assessed as inhibition of viral replication	[PMID: 19356827]
CHO	IC₅₀	0.051 μM Compound: AMD3100	Competitive binding affinity to CXCR4 receptor (unknown origin) expressed in CHO cells incubated for 40 mins by 12G5 antibody based fluorescence analysis Competitive binding affinity to CXCR4 receptor (unknown origin) expressed in CHO cells incubated for 40 mins by 12G5 antibody based fluorescence analysis	[PMID: 30978562]
CHO	IC₅₀	65 nM Compound: AMD3100	Binding affinity to CXCR4 (unknown origin) expressed in CHO cells measured after 40 mins by 12G5 antibody competition assay Binding affinity to CXCR4 (unknown origin) expressed in CHO cells measured after 40 mins by 12G5 antibody competition assay	[PMID: 27658790]
CHO-K1	IC₅₀	0.04 nM Compound: AMD-3100	Displacement of [125I]SDF1alpha from CCR2/CXCR4 expressed in CHOK1 cells Displacement of [125I]SDF1alpha from CCR2/CXCR4 expressed in CHOK1 cells	[PMID: 17715128]
CHO-K1	IC₅₀	0.09 nM Compound: AMD-3100	Displacement of [125I]MCP1 from CCR2/CXCR4 expressed in CHOK1 cells Displacement of [125I]MCP1 from CCR2/CXCR4 expressed in CHOK1 cells	[PMID: 17715128]
CHO-K1	IC₅₀	0.81 nM Compound: AMD-3100	Displacement of [125I]SDF1alpha from CXCR4 expressed in CHOK1 cells Displacement of [125I]SDF1alpha from CXCR4 expressed in CHOK1 cells	[PMID: 17715128]
GHOST CCR5	IC₅₀	>5 μM Compound: AMD-3100	Inhibitory concentration of compound against HIV-1 Ba1 strain in GHOST CCR5 cell line Inhibitory concentration of compound against HIV-1 Ba1 strain in GHOST CCR5 cell line	[PMID: 14698189]
GHOST CXCR4	IC₅₀	0.00095 μM Compound: AMD-3100	Inhibitory concentration of compound against HIV-1 LAI strain in GHOST CXCR4 cell line Inhibitory concentration of compound against HIV-1 LAI strain in GHOST CXCR4 cell line	[PMID: 14698189]
HEK293	IC₅₀	>1000 nM Compound: AMD-3100	Inhibition of Mab 12G5 binding to CXCR4 D171A mutant expressed in HEK293 cells Inhibition of Mab 12G5 binding to CXCR4 D171A mutant expressed in HEK293 cells	[PMID: 19451305]
HEK293	IC₅₀	>1000 nM Compound: AMD-3100	Inhibition of Mab 12G5 binding to CXCR4 D262A mutant expressed in HEK293 cells Inhibition of Mab 12G5 binding to CXCR4 D262A mutant expressed in HEK293 cells	[PMID: 19451305]
HEK293	IC₅₀	>1000 nM Compound: AMD-3100	Inhibition of Mab 12G5 binding to CXCR4 E288A/L290A mutant expressed in HEK293 cells Inhibition of Mab 12G5 binding to CXCR4 E288A/L290A mutant expressed in HEK293 cells	[PMID: 19451305]
HEK293	IC₅₀	143.7 nM Compound: AMD-3100	Inhibition of Mab 12G5 binding to CXCR4 D181A mutant expressed in HEK293 cells Inhibition of Mab 12G5 binding to CXCR4 D181A mutant expressed in HEK293 cells	[PMID: 19451305]
HEK293	IC₅₀	175.3 nM Compound: AMD-3100	Inhibition of Mab 12G5 binding to CXCR4 V280A mutant expressed in HEK293 cells Inhibition of Mab 12G5 binding to CXCR4 V280A mutant expressed in HEK293 cells	[PMID: 19451305]
HEK293	IC₅₀	196.6 nM Compound: AMD-3100	Inhibition of Mab 12G5 binding to CXCR4 V112A mutant expressed in HEK293 cells Inhibition of Mab 12G5 binding to CXCR4 V112A mutant expressed in HEK293 cells	[PMID: 19451305]
HEK293	IC₅₀	2.3 nM Compound: AMD-3100	Antiviral activity against T20-resistant HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of viral replication after 2 days Antiviral activity against T20-resistant HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of viral replication after 2 days	[PMID: 19451305]
HEK293	IC₅₀	213.1 nM Compound: 1; AMD3100	Displacement of [125I]CXCL12 from human CXCR4 expressed in HEK293 cell membranes after 1.5 hrs by Topcount method Displacement of [125I]CXCL12 from human CXCR4 expressed in HEK293 cell membranes after 1.5 hrs by Topcount method	[PMID: 29314840]
HEK293	IC₅₀	235.6 nM Compound: AMD-3100	Inhibition of Mab 12G5 binding to CXCR4 E275A mutant expressed in HEK293 cells Inhibition of Mab 12G5 binding to CXCR4 E275A mutant expressed in HEK293 cells	[PMID: 19451305]
HEK293	IC₅₀	258.5 nM Compound: AMD-3100	Inhibition of Mab 12G5 binding to CXCR4 V99A mutant expressed in HEK293 cells Inhibition of Mab 12G5 binding to CXCR4 V99A mutant expressed in HEK293 cells	[PMID: 19451305]
HEK293	IC₅₀	259 nM Compound: AMD-3100	Inhibition of Mab 12G5 binding to CXCR4 H203A mutant expressed in HEK293 cells Inhibition of Mab 12G5 binding to CXCR4 H203A mutant expressed in HEK293 cells	[PMID: 19451305]
HEK293	IC₅₀	265.8 nM Compound: AMD-3100	Inhibition of Mab 12G5 binding to CXCR4 I284A mutant expressed in HEK293 cells Inhibition of Mab 12G5 binding to CXCR4 I284A mutant expressed in HEK293 cells	[PMID: 19451305]
HEK293	IC₅₀	289.1 nM Compound: AMD-3100	Inhibition of Mab 12G5 binding to wild type CXCR4 expressed in HEK293 cells Inhibition of Mab 12G5 binding to wild type CXCR4 expressed in HEK293 cells	[PMID: 19451305]
HEK293	IC₅₀	296.4 nM Compound: AMD-3100	Inhibition of Mab 12G5 binding to CXCR4 H113A mutant expressed in HEK293 cells Inhibition of Mab 12G5 binding to CXCR4 H113A mutant expressed in HEK293 cells	[PMID: 19451305]
HEK293	IC₅₀	300.2 nM Compound: AMD-3100	Inhibition of Mab 12G5 binding to CXCR4 W283A mutant expressed in HEK293 cells Inhibition of Mab 12G5 binding to CXCR4 W283A mutant expressed in HEK293 cells	[PMID: 19451305]
HEK293	IC₅₀	4.6 nM Compound: AMD-3100	Antiviral activity against HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of viral replication after 2 days Antiviral activity against HIV1 NL4-3 infected in HEK293 cells assessed as inhibition of viral replication after 2 days	[PMID: 19451305]
HEK293	IC₅₀	469.5 nM Compound: AMD-3100	Inhibition of Mab 12G5 binding to CXCR4 E277A mutant expressed in HEK293 cells Inhibition of Mab 12G5 binding to CXCR4 E277A mutant expressed in HEK293 cells	[PMID: 19451305]
HEK293	IC₅₀	5.3 nM Compound: AMD-3100	Antiviral activity against multidrug resistant HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days Antiviral activity against multidrug resistant HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days	[PMID: 19451305]
HEK293	IC₅₀	6.2 nM Compound: AMD-3100	Antiviral activity against HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days Antiviral activity against HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days	[PMID: 19451305]
HEK293	IC₅₀	7 nM Compound: AMD-3100	Antiviral activity against NNRTI-resistant HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days Antiviral activity against NNRTI-resistant HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days	[PMID: 19451305]
HEK293	IC₅₀	72.7 nM Compound: AMD-3100	Inhibition of Mab 12G5 binding to CXCR4 H281A mutant expressed in HEK293 cells Inhibition of Mab 12G5 binding to CXCR4 H281A mutant expressed in HEK293 cells	[PMID: 19451305]
HEK293	IC₅₀	9 nM Compound: AMD-3100	Antiviral activity against NRTI-resistant HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days Antiviral activity against NRTI-resistant HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days	[PMID: 19451305]
HEK293	IC₅₀	9.2 nM Compound: AMD-3100	Antiviral activity against PI-resistant HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days Antiviral activity against PI-resistant HIV1 HXB2 infected in HEK293 cells assessed as inhibition of viral replication after 2 days	[PMID: 19451305]
HL-60	IC₅₀	15.2 μM Compound: 1, AMD-3100	Displacement of [125I]SDF1alpha from CXCR4 in human HL60 cells Displacement of [125I]SDF1alpha from CXCR4 in human HL60 cells	[PMID: 19188071]
HuT78	CC₅₀	241 μM Compound: 1	Cellular cytotoxicity against HUT-78 cells. Cellular cytotoxicity against HUT-78 cells.	[PMID: 7562918]
Jurkat	IC₅₀	27.4 nM Compound: 1, AMD-3100	Antagonist activity at CXCR4 in human Jurkat cells assessed as inhibition of SDF1-induced cell migration Antagonist activity at CXCR4 in human Jurkat cells assessed as inhibition of SDF1-induced cell migration	[PMID: 19188071]
MT4	CC₅₀	>10 μg/mL Compound: AMD-3100	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 23157587]
MT4	CC₅₀	>10 μM Compound: AMD-3100	Concentration of compound causing 50% death of uninfected cells Concentration of compound causing 50% death of uninfected cells	[PMID: 14698189]
MT4	CC₅₀	>421 μM Compound: 1, AMD-3100	Cytotoxicity against human MT4 cells after 4 days by MTT method Cytotoxicity against human MT4 cells after 4 days by MTT method	[PMID: 20043638]
MT4	CC₅₀	>421 μM Compound: 10d	Concentration required to reduce the viability of mock infected cells by 50% Concentration required to reduce the viability of mock infected cells by 50%	[PMID: 8568797]
MT4	CC₅₀	>50 μM Compound: AMD3100	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 26094944]
MT4	CC₅₀	>50 μM Compound: AMD3100	Cytotoxicity against human MT4 cells by MTT assay in presence of 10 uM of chloroquine Cytotoxicity against human MT4 cells by MTT assay in presence of 10 uM of chloroquine	[PMID: 26094944]
MT4	CC₅₀	>50 μM Compound: AMD3100	Cytotoxicity against human MT4 cells by MTT assay in presence of 2.5 uM of chloroquine Cytotoxicity against human MT4 cells by MTT assay in presence of 2.5 uM of chloroquine	[PMID: 26094944]
MT4	CC₅₀	>50 μM Compound: AMD3100	Cytotoxicity against human MT4 cells by MTT assay in presence of 5 uM of chloroquine Cytotoxicity against human MT4 cells by MTT assay in presence of 5 uM of chloroquine	[PMID: 26094944]
MT4	CC₅₀	>50 μM Compound: AMD3100	Cytotoxicity against Human immunodeficiency virus 1 NL4-3 infected in human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay Cytotoxicity against Human immunodeficiency virus 1 NL4-3 infected in human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay	[PMID: 32305183]
MT4	CC₅₀	>50 μM Compound: AMD3100	Cytotoxicity against in human MT-4 after 5 days by MTT assay Cytotoxicity against in human MT-4 after 5 days by MTT assay	[PMID: 33316719]
MT4	CC₅₀	50 μM Compound: 37	Concentration required to cause 50% death of uninfected MT-4 cells Concentration required to cause 50% death of uninfected MT-4 cells	[PMID: 9925728]
MT4	CC₅₀	6.5 μM Compound: AMD-3100	Cytotoxicity against human MT4 cells by MTT assay Cytotoxicity against human MT4 cells by MTT assay	[PMID: 19356827]
MT4	EC₅₀	0.004 μM Compound: 1, AMD-3100	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus replication after 4 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as inhibition of virus replication after 4 days by MTT assay	[PMID: 20043638]
MT4	EC₅₀	0.0042 μM Compound: 10d	Effective concentration against HIV-1(IIIB) replication in MT-4 cells Effective concentration against HIV-1(IIIB) replication in MT-4 cells	[PMID: 8568797]
MT4	EC₅₀	0.0059 μM Compound: 10d	Effective concentration against HIV-2(ROD) replication in MT-4 cells Effective concentration against HIV-2(ROD) replication in MT-4 cells	[PMID: 8568797]
MT4	EC₅₀	0.008 μM Compound: AMD3100	Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 20 passages selected in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.008 μM Compound: AMD3100	Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 40 passages selected in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.008 μM Compound: AMD3100	Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound Antiviral activity against HIV 1 RIN HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay after 60 passages selected in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.014 μM Compound: AMD3100	Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 RIN harboring integrase gene infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	EC₅₀	0.025 μM Compound: AMD3100	Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 5 uM of chloroquine Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 5 uM of chloroquine	[PMID: 26094944]
MT4	EC₅₀	0.028 μM Compound: AMD3100	Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound Antiviral activity against HIV 1 3B harboring integrase L34M mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 40 passages in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.032 μM Compound: AMD3100	Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay	[PMID: 26094944]
MT4	EC₅₀	0.034 μM Compound: AMD3100	Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay Antiviral activity against HIV 1 3B infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay	[PMID: 18378713]
MT4	EC₅₀	0.039 μM Compound: AMD3100	Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 2.5 uM of chloroquine Antiviral activity against T-cell line-tropic HIV1 NL4-3 infected in human MT4 cells assessed as inhibition of virus-induced cytopathogenicity after 5 days by MTT assay in presence of 2.5 uM of chloroquine	[PMID: 26094944]
MT4	EC₅₀	0.049 μM Compound: AMD3100	Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound Antiviral activity against HIV 1 3B harboring integrase E92Q S230N double mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 20 passages in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.056 μM Compound: AMD3100	Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound Antiviral activity against HIV 1 3B harboring integrase E92Q, S230N and L34M triple mutant infected in MT-4 cells assessed as inhibition of virus-induced cytopathic effect by MTT assay selected after 60 passages in presence of compound	[PMID: 18378713]
MT4	EC₅₀	0.065 μM Compound: AMD-3100	Effective concentration of compound against HIV-1 IIIB strain in MT-4 cells Effective concentration of compound against HIV-1 IIIB strain in MT-4 cells	[PMID: 14698189]
MT4	EC₅₀	10 μM Compound: 37	Concentration required to inhibit syncytia formation by 50% on HIV-1 infected MT-4 cells Concentration required to inhibit syncytia formation by 50% on HIV-1 infected MT-4 cells	[PMID: 9925728]
MT4	EC₅₀	2 nM Compound: AMD3100; 15c; 16c	Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV1 3B infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26974376]
MT4	EC₅₀	2 nM Compound: AMD3100; 15c; 16c	Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay Antiviral activity against HIV2 ROD infected in human MT4 cells assessed as reduction in virus-induced cytopathic effect after 5 days by MTT assay	[PMID: 26974376]
MT4	IC₅₀	0.017 μg/mL Compound: AMD-3100	Antiviral activity against X4 HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of viral replication pre-incubated for 30 mins measured 5 days post infection by MTT assay Antiviral activity against X4 HIV1 NL4.3 infected in human MT4 cells assessed as inhibition of viral replication pre-incubated for 30 mins measured 5 days post infection by MTT assay	[PMID: 23157587]
MT4	IC₅₀	0.41 μM Compound: AMD-3100	Antiviral activity against HIV1 3B in human MT4 cells assessed as inhibition of viral replication Antiviral activity against HIV1 3B in human MT4 cells assessed as inhibition of viral replication	[PMID: 19356827]
MT4	IC₅₀	1.5 ng/mL Compound: AMD-3100	Antiviral activity against HIV1 NL4.3 in human MT4 cells Antiviral activity against HIV1 NL4.3 in human MT4 cells	[PMID: 17452489]
PBMC	CC₅₀	>10 μg/mL Compound: AMD-3100	Cytotoxicity against human PBMC cells by MTT assay Cytotoxicity against human PBMC cells by MTT assay	[PMID: 23157587]
PBMC	CC₅₀	>10 μM Compound: 1a, AMD-3100	Cytotoxicity against PBMC Cytotoxicity against PBMC	[PMID: 17000109]
PBMC	CC₅₀	>10 μM Compound: AMD-3100	Concentration of compound causing 50% death of uninfected cells Concentration of compound causing 50% death of uninfected cells	[PMID: 14698189]
PBMC	EC₅₀	0.0038 μM Compound: AMD-3100	Effective concentration of compound against HIV-1 89.6 strain in PBMC cells Effective concentration of compound against HIV-1 89.6 strain in PBMC cells	[PMID: 14698189]

In Vitro

Anti-cancerCytokines & ChemokinesViral InfectionApoptosisCytokines and ChemokinesOthers

Anti-cancer

Plerixafor (10-1000 ng/mL; 24 h) inhibits ECMatrix invasion of SW480 colorectal cancer cells, with 1000 ng/mL producing an inhibition rate of 77.23%^[7].
Plerixafor (10-1000 ng/mL; 24 h) reduces VEGF and MMP-9 protein expression in SW480 colorectal cancer cells in a dose-dependent manner^[7].
Plerixafor (10-1000 ng/mL; 24 h) downregulates MMP-9 mRNA in SW480 colorectal cancer cells, and the reported relative optical density expression of MMP-9 is 17.58%^[7].
Plerixafor (0.5 µg/mL; 30 min) inhibits SDF-1-induced invasion of 4T1 cells through Matrigel by 70%^[9].

Anti-cancer

Cytokines & Chemokines

Plerixafor (AMD 3100; JM3100; SID791) (10-1000 ng/mL; exposure for 2 h) reduces CXCL12-stimulated SW480 colorectal cancer cell proliferation in a dose-dependent manner, with 1000 ng/mL decreasing the proliferation rate to 3.58^[7].
Plerixafor (10-1000 ng/mL; pretreatment for 15 min; migration for 3 h) inhibits CXCL12-induced chemotactic migration of SW480 colorectal cancer cells, with 1000 ng/mL producing an inhibition rate of 62.37%^[7].

Anti-cancer

Viral Infection

Plerixafor (5 days) inhibits the cytopathic effect of HIV-1 NL4.3 in MT-4 cells, with an EC₅₀ of 0.011 µM^[11].

Apoptosis

Cytokines & Chemokines

Plerixafor (62.5 μg/mL; 24 h) induces 13.9% late apoptosis in TGFβ-activated HSC-T6 cells^[2].

Cytokines and Chemokines

Plerixafor (500 ng/mL; up to 50 h) only causes a transient 2-3 h increase in SDF-1α in the supernatant of human bone marrow MSC (M1), without long-term effects^[1].
Plerixafor (500 ng/mL; 0-12 h) transiently depletes intracellular SDF-1α at 2 h in human bone marrow MSC (M1/hPL) and recovers by 4 h, whereas CXCR4 expression remains unchanged within 8 h^[1].
Plerixafor (500 ng/mL; 4 h) almost completely antagonizes SDF-1α (100 ng/mL)-stimulated Transwell migration of human CD34⁺ HPCs^[1].
Plerixafor (300 nM; 30 min-1 h) acts as a CXCR4 antagonist in U2OS EGFP-CXCR4 cells, inhibiting SDF-1α-induced CXCR4 translocation^[2].
Plerixafor (0-20 μg/mL; 1-2 h) reduces CXCR4-mediated C6-AMD liposome uptake in HSC-T6 cells at 10 and 20 μg/mL^[2].
Plerixafor (62.5 μg/mL; 6-24 h) reduces P-p38 expression by 29% in TGFβ-activated HSC-T6 cells^[2].
Plerixafor (0.2 µg/mL; 30 min) inhibits SDF-1-induced CXCR4 internalization in U2OS cells^[9].
Plerixafor (0.6 µg/mL; 1 h) reduces CXCR4-mediated DOX-AMD-DNG uptake in 4T1 cells^[9].
Plerixafor (20 µM-1 h) inhibits the binding of the anti-CXCR4 antibody 12G5 to Jurkat cells by 90%^[11].
Plerixafor (15 min) inhibits CXCL12-induced calcium signaling in U87.CXCR4 cells with an IC₅₀ of 0.120 µM^[11].

Others

Plerixafor (8-1000 μg/mL; 24 h) reduces HSC-T6 cell viability at higher concentrations, whereas the liposomal formulation shows lower cytotoxicity at the same concentrations^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence^[2]

Cell Line:

U2OS cells stably expressing EGFP-CXCR4
Concentration:

300 nM (free Plerixafor solution); 10 nM (SDF-1α)
Incubation Time:

30 min; 1 h
Result:

Produced a diffuse green fluorescence pattern at 300 nM, indicating inhibition of SDF-1α-induced CXCR4 translocation to endosomes.

Cell Viability Assay^[2]

Cell Line:

HSC-T6 rat hepatic stellate cells
Concentration:

8, 16, 31, 62, 125, 250, 500, and 1000 μg/mL (free Plerixafor solution)
Incubation Time:

24 h
Result:

HSC-T6 cells retained high viability at 8, 16, 31, and 62 μg/mL and showed reduced viability at 125, 250, 500, and 1000 μg/mL.
Liposomal formulation showed higher cell viability at matched concentrations.

Apoptosis Analysis^[2]

Cell Line:

TGFβ-activated HSC-T6 cells
Concentration:

62.5 μg/mL (free Plerixafor solution); 10 ng/mL (TGFβ)
Incubation Time:

24 h exposure
Result:

Induced 13.9% late apoptosis (Q1-UR) in TGFβ-activated HSC-T6 cells.

Western Blot Analysis^[2]

Cell Line:

TGFβ-activated HSC-T6 cells
Concentration:

62.5 μg/mL (free Plerixafor solution); 2 ng/mL (TGFβ)
Incubation Time:

24 h exposure; 6 h (TGFβ)
Result:

Reduced P-p38 expression by 29% in TGFβ-activated HSC-T6 cells compared with untreated activated cells.

Cell Viability Assay^[7]

Cell Line:

SW480 human colorectal cancer cells
Concentration:

10, 100, 1000 ng/mL
Incubation Time:

2 h (exposure); 24, 48, 72 h (MTT)
Result:

Proliferation rate of CXCL12-stimulated SW480 cells was reduced to 6.10 at 10 ng/mL, 4.49 at 100 ng/mL, and 3.58 at 1000 ng/mL after 72 h.

Cell Invasion Assay^[7]

Cell Line:

SW480 human colorectal cancer cells
Concentration:

10, 100, 1000 ng/mL
Incubation Time:

24 h
Result:

SW480 invasion was reduced, with A590 values of 0.656 at 10 ng/mL, 0.505 at 100 ng/mL, and 0.158 at 1000 ng/mL.
Inhibition rates were 7.57% at 10 ng/mL, 28.43% at 100 ng/mL, and 77.23% at 1000 ng/mL.

Cell Migration Assay ^[7]

Cell Line:

SW480 human colorectal cancer cells
Concentration:

10, 100, 1000 ng/mL
Incubation Time:

15 min (pretreatment); 3 h (migration assay)
Result:

CXCL12-induced chemotactic migration of SW480 cells was reduced in a dose-dependent manner.
Inhibition rates were 5.24% at 10 ng/mL, 47.27% at 100 ng/mL, and 62.37% at 1000 ng/mL.

Western Blot Analysis^[7]

Cell Line:

SW480 human colorectal cancer cells
Concentration:

10, 100, 1000 ng/mL
Incubation Time:

24 h
Result:

After 24 h, MMP-9 and VEGF protein expression were reduced in a dose-dependent manner in SW480 cells.
MMP-2 protein was not described as reduced.

RT-PCR^[7]

Cell Line:

SW480 human colorectal cancer cells
Concentration:

10, 100, 1000 ng/mL
Incubation Time:

24 h
Result:

After 24 h, RT-PCR showed downregulation of MMP-9 mRNA in SW480 cells at 100 and 1000 ng/mL.
MMP-2 and VEGF mRNAs were not downregulated.
Densitometric analysis reported relative expression decreased to 17.58% for MMP-9 and 39.44% for VEGF compared with controls.

Cell Invasion Assay^[9]

Cell Line:

4T1 cells
Concentration:

0.5 µg/mL (30 min preincubation); 20 nM (SDF-1)
Incubation Time:

30 min (preincubation); 24 h (invasion)
Result:

Inhibited 4T1 cell invasion through Matrigel by 70%.

In Vivo

Innate ImmunityAdaptive ImmunityCytokines & ChemokinesLocal Vascular RegulationOthers

Innate Immunity

Plerixafor (200 μg/day; subcutaneous injection; continuous infusion) increases circulating and intrahepatic leukocytes, especially neutrophils, in healthy mice without inducing liver injury^[4].
Plerixafor (200 μg/day; subcutaneous injection; continuous infusion) aggravates chronic CCl₄-induced liver fibrosis and increases circulating and intrahepatic neutrophils^[4].
Plerixafor (100 μg; intraperitoneal injection; single administration; 12 hours after CCl₄ administration) does not attenuate liver injury and increases intrahepatic neutrophils at 36 hours^[4].

Innate Immunity

Adaptive Immunity

Plerixafor (AMD 3100; JM3100; SID791) (5 mg/kg; intraperitoneal injection; once daily; 1 week (days 1 to 7 after exposure to crystalline silica)) attenuates crystalline silica-induced pulmonary inflammation and fibrosis in a silicosis mouse model^[5].

Innate Immunity

Cytokines & Chemokines

Plerixafor (1 mg/kg/day; intraperitoneal injection; once daily for 3 consecutive days of observation) reduces ischemic infarct volume and brain edema after permanent MCAO in mice, limits leukocyte infiltration and proinflammatory cytokine expression, protects BBB integrity, and improves neurological functional outcomes^[12].

Local Vascular Regulation

Plerixafor (5 mg/kg/day; subcutaneous injection) mobilizes KDR⁺endothelial progenitor cells into the peripheral blood of healthy New Zealand white rabbits^[10].
Plerixafor (5 mg/kg/day; subcutaneous injection into the vastus lateralis muscle; once daily for 4 weeks of continuous observation) promotes neointima formation and endothelialization at the aneurysm neck after flow diverter implantation in New Zealand white rabbits^[10].

Local Vascular Regulation

Innate Immunity

Plerixafor (1 g/L; subconjunctival injection 5 µL; once daily; 7 days) reduces alkali burn-induced corneal neovascularization and inflammatory cell infiltration in C57BL/6 mice without increasing circulating EPCs^[6].
Plerixafor (2.5 mg/kg; intraperitoneal injection; once daily; 7 days) mobilizes circulating EPCs but does not reduce alkali burn-induced corneal neovascularization in C57BL/6 mice^[6].

Others

Plerixafor (5 mg/kg; intraperitoneal injection; administered once on day 5) mobilizes CFU-F-forming mesenchymal cells into the peripheral blood of female multiparous Wistar rats after VEGF administration^[3].
Plerixafor (5 mg/kg; intraperitoneal injection; administered once on day 5) improves fracture healing in a delayed femoral osteotomy healing model in female Wistar rats after VEGF exposure, increasing the RUST score, bone volume, trabecular thickness, and bone formation while reducing fibrous tissue^[3].
Plerixafor (200 μg dissolved in 100 μL PBS; intraperitoneal injection; once weekly; administered 12 hours after the last CCl₄ injection) does not alter chronic CCl₄-induced fibrosis or intrahepatic inflammatory cell content^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Wistar (female, ex-breeder, 380-600 g)^[3]
Dosage:

5 mg/kg
Administration:

i.p.; once on day 5
Result:

The mobilized group formed CFU-Fs in 6 of 8 individual cultures; no CFUs were isolated from non-mobilized control blood.
Mean CFU-F/mL was 2.9 in the mobilized group versus no CFUs in controls.

Animal Model:

Wistar (female, 12-14 weeks old, 230-300 g)^[3]
Dosage:

5 mg/kg
Administration:

i.p.; once on day 5
Result:

RUST score was 9.63 in the VEGF group versus 7.71 in controls.
MicroCT bone volume was 5.22 µm³ versus 4.31 µm³; trabecular thickness was 0.05 mm versus 0.04 mm; tissue volume was 10.03 µm³ versus 9.23 µm³; trabecular separation was 0.08 mm versus 0.07 mm; trabecular number was 10.99 1/µm versus 14.09 1/µm; total porosity was 47.48% versus 46.21%.
Histomorphometry bone was 55.1% versus 39.1%; cartilage was 40.9% versus 43.1%; fibrous tissue was 0.3% versus 15.3%; vascular tissue was 3.9% versus 2.4%; combined bone and cartilage was 96% versus 82.3%.

Animal Model:

C57Bl/6 (male)^[4]
Dosage:

200 μg/day
Administration:

s.c.; continuous infusion
Result:

Circulating leukocytes were 12×10⁶/mL versus 5×10⁶/mL in oil controls, with an increase in circulating neutrophils.
Intrahepatic CD45⁺ cells were 2.4×10⁶/g versus 1.4×10⁶/g, with an increase in intrahepatic neutrophils.
Did not induce an injury response.

Animal Model:

C57Bl/6 (male)^[4]
Dosage:

200 μg/day
Administration:

s.c.; continuous infusion
Result:

Increased hepatic collagen content and fibrosis by Sirius red staining and increased hepatic α-SMA staining.
Collagen 1α1 and α-SMA transcript levels were increased approximately 2-fold.
Circulating leukocytes were 13×10⁶/mL versus 6×10⁶/mL in CCl₄ alone, with increased circulating neutrophils.
Intrahepatic CD45⁺ cells were 4×10⁶/g versus 2.5×10⁶/g in CCl₄ alone, with increased total intrahepatic neutrophils.

Animal Model:

C57Bl/6 (male)^[4]
Dosage:

200 μg in 100 μL PBS
Administration:

i.p.; once weekly; 12 hours after last CCl4 injection
Result:

Did not change the extent of fibrosis by Sirius red staining or the absolute number of intrahepatic CD45⁺ inflammatory cells.

Animal Model:

C57Bl/6 (male)^[4]
Dosage:

100 μg
Administration:

i.p.; once; 12 hours after CCl₄ administration
Result:

Serum ALT and AST were not different from control.
Histological necrosis score showed a trend toward increase at 36 hours.
Intrahepatic CD45⁺ cells showed a trend toward increase at 36 and 72 hours.
Intrahepatic neutrophils at 36 hours were 15×10⁵ versus 5×10⁵ cells/g.
LSK hematopoietic stem cells increased in the liver at 36 hours.

Animal Model:

C57BL/6 (male, 10-12 weeks old)^[5]
Dosage:

5 mg/kg
Administration:

intraperitoneal; once daily; 1 week (days 1-7 after crystalline silica exposure)
Result:

Reduced inflammatory cell infiltration and alveolar wall thickening at days 7 and 14 and delayed nodule formation.
Pathology scores were lower than in CS-exposed mice on days 7, 14, and 28.
Prevented CS-induced weight loss, with body weight gradually recovering and returning to the original level by day 28.
Reduced lung CXCR4 and CXCL12 expression at day 28 by immunohistochemistry and reduced CXCR4 expression at day 7 by Western blotting.
Reduced MPO expression/neutrophil infiltration in lung tissue on days 7, 14, and 28 and reduced NET formation (MPO⁺citH3⁺ cells) at day 28.
Reduced the number and size of peribronchial B-lymphoid aggregates and reduced CD45R⁺ B cells in lung tissue at day 28.
Increased peripheral blood CD19⁺ B cells at days 7 and 14.
Proliferating B cells were not detected in lung tissue, and Ki67 was absent in lymphoid aggregates.
Reduced collagen deposition by Masson staining and lowered Ashcroft fibrosis scores on days 7, 14, and 28.
Reduced collagen I and α-SMA expression in lung tissue at days 14 and 28.
Reduced lung infiltration of CD45⁺collagen I⁺CXCR4⁺ circulating fibrocytes on days 7 and 28.

Animal Model:

C57BL/6 (male, 8 weeks old)^[6]
Dosage:

1 g/L solution, 5 µL per subconjunctival injection
Administration:

subconjunctival injection; once daily; 7 days
Result:

Microvascular density was 7.6 vessels per 0.034 mm² at 7 days and 11.7 vessels per 0.034 mm² at 14 days.
PMN counts were 12.4 at 7 days and 10.0 at 14 days.
EPC number was 0.05 at baseline, 0.07 at 0.5 hours, 0.06 at 1 hour, 0.07 at 6 hours, 0.06 at 1 day, 0.07 at 4 days, and 0.06 at 7 days.
Inflammatory index decreased at 5, 7, 10, and 14 days relative to the other groups.
VEGFR2 and CD34 immunohistochemical positive index was lower at 7 and 14 days than in the other groups.

Animal Model:

C57BL/6 (male, 8 weeks old)^[6]
Dosage:

2.5 mg/kg per day
Administration:

intraperitoneal injection; once daily; 7 days
Result:

Microvascular density was 13.2 vessels per 0.034 mm² at 7 days and 16.8 vessels per 0.034 mm² at 14 days.
PMN counts were 16.2 at 7 days and 15.0 at 14 days.
EPC number was 0.05 at baseline, 0.11 at 0.5 hours, 0.25 at 1 hour, 0.27 at 6 hours, 0.36 at 1 day, 0.23 at 4 days, and 0.12 at 7 days.
VEGFR2 and CD34 immunohistochemical positive index was higher than in the other three groups at 7 days and higher than in the subconjunctival group at 14 days.
Corneal inflammation index and neovascular density did not differ from controls, with no inhibition of angiogenesis.

Animal Model:

New Zealand White (male, 10-12 months, 3-3.5 kg)^[10]
Dosage:

5 mg/kg/day
Administration:

s.c. at vastus lateralis; daily; 4 weeks (qPCR cohort)
Result:

At 2 and 4 weeks after flow-diverter implantation, more endothelial-like cells were in the neointima than in the control group; at 4 weeks, the endothelial-like cell count ratio was 92:60.
Hard tissue sections and Masson trichrome staining showed that the neointima was more intact and thicker than in the control group.
At 4 weeks, neointimal mRNA levels of Tie2, KDR, and VE-cadherin were higher than in controls; CD34 mRNA did not differ between groups.

Animal Model:

CD-1 (adult male, 25-30 g)^[12]
Dosage:

1 mg/kg/day
Administration:

i.p.; daily for 3 consecutive days starting immediately after MCAO
Result:

Infarct volume by cresyl violet staining was lower at 72 hours after MCAO.
Brain water content was reduced at 48 and 72 hours.
Neurological deficit score improved at 72 hours.
MPO-positive cells in the ipsilateral lesion cortex and basal ganglia were reduced at 48 and 72 hours.
MPO activity in the ischemic hemisphere was reduced at 48 and 72 hours.
MPO protein was mildly attenuated.
TNF-α and IL-6 mRNA levels were reduced at 24 hours.
TNF-α and IL-6 protein levels were reduced at 48 hours.
IFN-γ protein was reduced at 48 hours.
CD40L, IL-1α, and IL-1β mRNA/protein levels were not changed.
IgG leakage at 3 days after MCAO was alleviated.
Evans blue extravasation ratio was lower than in saline-treated MCAO mice.
Occludin/ZO-1 tight-junction disruption and relative gap formation were reduced.

Related Protocols :

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991			2011-05	PHASE1

Chemical Information

CAS. Nr. 110078-46-1
Appearance Solid
Molecular Weight 502.78
Formel C₂₈H₅₄N₈
Color White to off-white
SMILES

C1(CN2CCCNCCNCCCNCC2)=CC=C(C=C1)CN3CCNCCCNCCNCCC3
Synonyms

AMD 3100; JM3100; SID791
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (120)

All Cell Migration/Invasion AssayHistological Imaging/StainingIn Vivo ImagingRT-PCRWBCell Proliferation/Viability AssayIHCIF

Sort by:

Journal Impact Factor

Immunity

Small-molecule CBP/p300 histone acetyltransferase inhibition mobilizes leukocytes from the bone marrow via the endocrine stress response. [Abstract]

2024 Feb 13;57(2):364-378.e9. PMID: 38301651
Adv Mater

2026 Nov;38(61):e74954. PMID: 42728752
Cell Mol Immunol

NLRP3-dependent pyroptosis is required for HIV-1 gp120-induced neuropathology. [Abstract]

2020 Mar;17(3):283-299. PMID: 31320730

Plerixafor purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2020 Mar;17(3):283-299. [Abstract]

ELISA of IL-1β in supernatants of BV2 cells stimulated with gp120 LAV (0.5 μg/mL) for 24 h in the presence of increasing doses of a CXCR4-specific inhibitor (AMD3100, 0.1-10 μM; prestimulated with 30 min-2 h).
Bioact Mater

Phosphorylation inhibition of protein-tyrosine phosphatase 1B tyrosine-152 induces bone regeneration coupled with angiogenesis for bone tissue engineering. [Abstract]

2021 Jan 7;6(7):2039-2057. PMID: 33511306

Plerixafor purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2021 Jan 7;6(7):2039-2057. [Abstract]

Western blot analysis of the expression of CXCR4, integrin αvβ3, p-Jak2, Jak2, p-FAK, FAK, p-STAT3 and STAT3 in MSCs (pretreated with a CXCR4 inhibitor (AMD3100; 20 μM; pretreated with 1 h) and an integrin αvβ3 inhibitor (cyclo(-RGDfK))) after the addition of 152RM for 24 h.
Cell Stem Cell

Engineered MSCs enable bone marrow-targeted immunomodulation. [Abstract]

2026 Apr 2;33(4):660-675.e5. PMID: 41895281

Plerixafor purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2026 Apr 2;33(4):660-675.e5. [Abstract]

Crystal violet staining of migrated MSCs in Transwell chambers. Scale bars, 500 μm. The results showed that MSCGlg1migration toward primary BM cells was unaffected by the CXCR4 antagonist Plerixafor (AMD3100, 5 μM; 24 h). In contrast, Plerixafor (AMD3100) markedly inhibited the migration of unmodified MSCs toward tumor-conditioned medium.
Nat Cell Biol

Trafficking circuit of CD8+ T cells between the intestine and bone marrow governs antitumour immunity. [Abstract]

2024 Aug;26(8):1346-1358. PMID: 39039181
Nat Neurosci

2026 Sep 8. PMID: 42711429
Bone Res

A RANKL+/CXCR4+ B cell population accumulates in bone marrow and causes age-related osteoporosis in mice. [Abstract]

2026 May 18;14(1):53. PMID: 42151112

Plerixafor purchased from MedChemExpress. Usage Cited in: Bone Res. 2026 May 18;14(1):53. [Abstract]

FACS-sorted RCBs (RANKL⁺B220^hiIgM⁺) from 3- and 24-month-old mice were treated with vehicle or 50 μM Plerixafor for 2 h, then cultured in transwell plates coated with BdMPCs from 15-month-old WT or P-cKO mice, treated with vehicle or Plerixafor for 6 h, and stained with crystal violet. Plerixafor, a CXCR4 antagonist, effectively inhibited the age- and genotype-enhanced migration of RCBs toward bone-derived MPCs. Bar = 100 μm.

Plerixafor purchased from MedChemExpress. Usage Cited in: Bone Res. 2026 May 18;14(1):53. [Abstract]

Representative images showing ROSA^mTmG mouse-derived tdTomato⁺ cells (red) in metaphysis of tibiae from NSG mice treated with vehicle or Plerixafor (5 mg/kg; i.p.; once daily for 12 days), and the number of tdTomato⁺ cells. The results showed that the Plerixafor-treated recipients had significantly fewer tdTomato⁺ RCBs than the vehicle-treated recipients. Bar = 50 μm.
Bone Res

Neonatal bone marrow interstitial fluid supports expansion and osteogenic ability of human bone marrow mesenchymal stromal cells. [Abstract]

2025 Dec 15;13(1):102. PMID: 41392038

Plerixafor purchased from MedChemExpress. Usage Cited in: Bone Res. 2025 Dec 15;13(1):102. [Abstract]

Representative images and quantification data of migratory hBMSCs in the Transwell culture (see the Materials and Methods section for details). rhCXCL12, recombinant human CXCL12 protein; Plerixafor (AMD3100), the CXCR4 antagonist. Scale bar, 100 μm. The results showed that the administration of the CXCR4 antagonist Plerixafor (AMD3100, 50 nmol/L; 24 h) eliminated the increased migratory ability of NBIF-fed hBMSCs.
Adv Funct Mater

2026 Sep 4.
Adv Funct Mater

2025 Dec 16.
Adv Funct Mater

2024 Dec 23.
Adv Funct Mater

2020, 2000309.

Plerixafor purchased from MedChemExpress. Usage Cited in: Adv Funct Mater. 2020, 2000309.

NOD/SCID mice were i.p. injected with AMD3100 (4 mg/kg). After 1 h, the mice are i.v. injected with iFluor 647-labeled Aazo@CMSN. At 12 h after nanoparticle injection, the mouse craniums are excised for the observation of nanoparticle bone marrow niches targeting under CLSM. Pre-treatment with AMD3100 significantly declined the bone marrow niches targeting of the nanoparticles.
Nat Commun

Nef stabilizes actin to prevent HIV-1 sensing by RIG-I-like receptors. [Abstract]

2025 Dec 7;16(1):10945. PMID: 41354661
J Nanobiotechnology

CXCR4-engineered fibroblast membrane nanovesicles for Photothermal-enhanced ferroptotic therapy through chemokine-navigated tumor homing. [Abstract]

2025 Dec 30;24(1):102. PMID: 41462305

Plerixafor purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Dec 30;24(1):102. [Abstract]

In vivo IR780 distribution in MDA-MB-468 tumor-bearing mice at different time points after i.v. injection of FbM@IR NPs, FbM@IR NPs + Plerixafor (3.1 mg/kg; i.p.; single dose), FbM@IR NPs + LIT-927 and CTR-FbM@IR NPs. (Green dashed circles indicate tumor sites).

Plerixafor purchased from MedChemExpress. Usage Cited in: J Nanobiotechnology. 2025 Dec 30;24(1):102. [Abstract]

In vivo IR780 distribution in KYSE-30 tumor-bearing mice at different time points after i.v. injection of FbM@IR NPs, FbM@IR NPs + Plerixafor (3.1 mg/kg; i.p.; single dose), FbM@IR NPs + LIT-927 and CTR-FbM@IR NPs. (Green dashed circles indicate tumor sites).
J Nanobiotechnology

The bone marrow mesenchymal stem cells derived migrasomes induced by Titania nanotubes surface serve as chemotaxis effect for osteogenesis. [Abstract]

2025 Aug 29;23(1):592. PMID: 40877924
Theranostics

CXCL12-mediated HOXB5 overexpression facilitates Colorectal Cancer metastasis through transactivating CXCR4 and ITGB3. [Abstract]

2021 Jan 1;11(6):2612-2633. PMID: 33456563

Plerixafor purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 Jan 1;11(6):2612-2633. [Abstract]

Caco-2 cells are incubated with vehicle or AMD3100 (1 µg/ml, 24 hours) after lentivirus transfection (LV-HOXB5), then Western blotting assays are conducted to measure the protein levels of CXCL12, HOXB5, CXCR4, p-ERK and p-ETS1 in the indicated cell lines.

Plerixafor purchased from MedChemExpress. Usage Cited in: Theranostics. 2021 Jan 1;11(6):2612-2633. [Abstract]

Transwell assays indicated that AMD3100 treatment (1 µg/ml, 24 hours) significantly decreases the migration and invasion of Caco-2-HOXB5 cells.
Adv Sci (Weinh)

Nanoparticle-Mediated CXCL12-CXCR4 Inhibition Reprograms Macrophages and Suppresses Gastric Carcinoma. [Abstract]

2025 Aug;12(30):e00225. PMID: 40536774
Cell Rep Med

Augment proteasome inhibitor efficacy activates CD8+ T cell-mediated antitumor immunity in breast cancer. [Abstract]

2025 Jul 15;6(7):102211. PMID: 40609539
Biomaterials

Engineered cell membrane vesicles loaded with lysosomophilic drug for acute myeloid leukemia therapy via organ-cell-organelle cascade-targeting. [Abstract]

2025 Jun:317:123091. PMID: 39778270
Research (Wash D C)

High Mobility Group Protein B1 Promotes Interferon Regulatory Factor 1 SUMOylation to Prime Trained Immunity of Circulating Monocytes and Aggravate the Progressive Synovial Inflammation in Knee Osteoarthritis. [Abstract]

2026 May 14:9:1243. PMID: 42146764
Research (Wash D C)

2026 Mar 19.
Cardiovasc Res

Periaortic lymphatic vessels protect against thoracic aortic dissection through mobilizing immune response. [Abstract]

2025 Nov 11:cvaf215. PMID: 41213294
Chem Eng J

2025 Oct 15.
Pharmacol Res

2026 Sep:231:108396. PMID: 42600760
Cell Death Dis

TREM2 deficiency in microglia accelerates photoreceptor cell death and immune cell infiltration following retinal detachment. [Abstract]

2023 Mar 28;14(3):219. PMID: 36977680
Cell Death Dis

PGK1 contributes to tumorigenesis and sorafenib resistance of renal clear cell carcinoma via activating CXCR4/ERK signaling pathway and accelerating glycolysis. [Abstract]

2022 Feb 4;13(2):118. PMID: 35121728

Plerixafor purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 Feb 4;13(2):118. [Abstract]

PGK1 induced the CXCR4-mediated phosphorylation of AKT (p-AKT) and ERK (p-ERK), and blockade of CXCR4 signaling by AMD3100 (48 h) treatment did not alter cellular PGK1 expression in KIRC cells.
Cell Death Dis

Hepatitis B virus X protein promotes the stem-like properties of OV6+ cancer cells in hepatocellular carcinoma. [Abstract]

2017 Jan 19;8(1):e2560. PMID: 28102846
Cancer Lett

CXCR4 inhibitor, AMD3100, down-regulates PARP1 expression and Synergizes with olaparib causing severe DNA damage in BRCA-proficient triple-negative breast cancer. [Abstract]

2022 Oct 7;551:215944. PMID: 36209974

Plerixafor purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2022 Oct 7;551:215944. [Abstract]

Viability of cells treated with combinations different concentrations of AMD3100 and Olaparib for 24 h.

Plerixafor purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2022 Oct 7;551:215944. [Abstract]

Immunohistochemical staining of proliferation-related protein, Ki-67, in breast cancer after treatment with control, AMD3100 (2.5 mg/kg), Olaparib, or a combination of AMD3100 and Olaparib.
J Immunother Cancer

Natural lung-tropic TH9 cells: a sharp weapon for established lung metastases. [Abstract]

2024 Dec 4;12(12):e009629. PMID: 39631847
Int J Biol Sci

SDF-1 in Mammary Fibroblasts of Bovine with Mastitis Induces EMT and Inflammatory Response of Epithelial Cells. [Abstract]

2017 May 5;13(5):604-614. PMID: 28539833

Plerixafor purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2017 May 5;13(5):604-614. [Abstract]

Epithelial cells with or without AMD3100 pretreatment are cultured in conditioned medium (CM) from LPS-treated NFs or LTA-treated NFs for 3 days, and the secretion of TNF-α in the supernatant of culture is detected by ELISA. Epithelial cells cultured in MSM are used as control. Both LPS-treated NFs and LTA-treated NFs enhanced the section of TNF-α by epithelial cells compared with control. Pretreatment of epithelial cells with AMD3100 significantly attenuates the increase of TNF-α.
J Neuroinflammation

CXCR4 and CXCR6 dually limit T cell entry into the polyomavirus-infected brain. [Abstract]

2025 Jun 28;22(1):169. PMID: 40581668
Phytomedicine

Wikstrol B reactivates latent human immunodeficiency virus (HIV-1) via the nuclear factor-κB (NF-κB) pathway. [Abstract]

2025 Jun:141:156667. PMID: 40233507
Mater Today Bio

Nanoparticles coated with osteoblast-like cell membranes as curcumin delivery vehicles for targeted postmenopausal osteoporosis therapy. [Abstract]

2025 Dec 9:36:102636. PMID: 41497898
Mater Today Bio

A biomimetic targeted nanosystem delivering synergistic inhibitors for glioblastoma immune microenvironment reprogramming and treatment. [Abstract]

2024 Sep 1:28:101222. PMID: 39296357
Nano Today

2022, 47: 101689.
Acta Pharmacol Sin

Lung memory B cells ameliorate Alzheimer's disease-like pathology in 5×FAD mice through the CXCL12-CXCR4 axis. [Abstract]

2025 Oct 17. PMID: 41107404
Cell Death Discov

CXCL12 alone is enough to Reprogram Normal Fibroblasts into Cancer-Associated Fibroblasts. [Abstract]

2025 Apr 8;11(1):156. PMID: 40199862
Acta Biomater

Chemotactic recruitment of genetically engineered cell membrane-camouflaged metal-organic framework nanoparticles for ischemic osteonecrosis treatment. [Abstract]

2024 Sep 1:185:410-428. PMID: 39029641
Acta Biomater

Nanoparticle-mediated blockade of CXCL12/CXCR4 signaling enhances glioblastoma immunotherapy: Monitoring early responses with MRI radiomics. [Abstract]

2024 Mar 15:177:414-430. PMID: 38360292
NPJ Precis Oncol

2026 Jul 21. PMID: 42481778
J Transl Med

BM-MSCs display altered gene expression profiles in B-cell acute lymphoblastic leukemia niches and exert pro-proliferative effects via overexpression of IFI6. [Abstract]

2023 Sep 5;21(1):593. PMID: 37670388
Proc Natl Acad Sci U S A

Structural mechanisms underlying the modulation of CXCR4 by diverse small-molecule antagonists. [Abstract]

2025 Mar 18;122(11):e2425795122. PMID: 40063796
Oncogene

CXCR4 and CXCR7 signaling promotes tumor progression and obesity-associated epithelial-mesenchymal transition in prostate cancer cells. [Abstract]

2022 Oct;41(41):4633-4644. PMID: 36088505
Oncogene

PDGFR-induced autocrine SDF-1 signaling in cancer cells promotes metastasis in advanced skin carcinoma. [Abstract]

2019 Jun;38(25):5021-5037. PMID: 30874597

Plerixafor purchased from MedChemExpress. Usage Cited in: Oncogene. 2019 Jun;38(25):5021-5037. [Abstract]

IF staining of the tumor tissue sections showed decreased Ki67 and a reversal of EMT markers indicated by increased E-cadherin and decreased N-cadherin expression in the AMD3100 (5 mg/kg or 3.5 mg/kg) treated groups.

Plerixafor purchased from MedChemExpress. Usage Cited in: Oncogene. 2019 Jun;38(25):5021-5037. [Abstract]

Additional EMT-related proteins (Snail and Slug) are downregulated by AMD3100 (5 mg/kg or 3.5 mg/kg) in tumor samples from both diet groups, as quantified by immunoblotting.
Leukemia

Distinct stromal cell populations define the B-cell acute lymphoblastic leukemia microenvironment. [Abstract]

2025 Aug 15. PMID: 40817406

Plerixafor purchased from MedChemExpress. Usage Cited in: Leukemia. 2025 Aug 15. [Abstract]

Effect of cytokine signaling blockade on ALL cell survival in co-culture with stromal populations. ALL cells were co-cultured with early mesenchymal progenitors, adipogenic progenitors, or cultured alone. Cell survival was assessed after treatment with blocking antibodies against IL7, Osteopontin, or the CXCR4 inhibitor Plerixafor (1 nM; 7 days), Mouse IgG1 kappa, Isotype Control (1 ug/mL; 7 days).
Int J Nanomedicine

Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment. [Abstract]

2023 Jul 31:18:4329-4346. PMID: 37545872
Fertil Steril

Protein kinase CK2 participates in estrogen-mediated endothelial progenitor cell homing to endometriotic lesions through stromal cells in a stromal cell-derived factor-1- CXCR4-dependent manner. [Abstract]

2020 May;113(5):1067-1079.e5. PMID: 32386617
Clin Transl Med

Multi-omics reveals a novel Cxcr4+ subpopulation of alveolar macrophages and therapeutic effect of AMD3100 in mice with advanced silicosis. [Abstract]

2026 Jun;16(6):e70705. PMID: 42204838
Brain Behav Immun

Ds-HMGB1 and fr-HMGB induce depressive behavior through neuroinflammation in contrast to nonoxid-HMGB1. [Abstract]

2017 Jan:59:322-332. PMID: 27647532
Pharmaceutics

Development and Evaluation of 1'-Acetoxychavicol Acetate (ACA)-Loaded Nanostructured Lipid Carriers for Prostate Cancer Therapy. [Abstract]

2021 Mar 24;13(4):439. PMID: 33804975
Biochem Pharmacol

Targeting the CXCR7 pathway with TC14012 to inhibit endothelial necroptosis and lung cancer metastasis. [Abstract]

2025 Jun:236:116852. PMID: 40049294
Cell Mol Life Sci

Crosstalk between purinergic receptor P2Y11 and chemokine receptor CXCR7 is regulated by CXCR4 in human macrophages. [Abstract]

2024 Mar 13;81(1):132. PMID: 38472446
Mol Ther Nucleic Acids

Mechanical stimuli-induced CCL2 restores adult mouse cells to regenerate hair follicles. [Abstract]

2023 Mar 10:32:94-110. PMID: 37020681
J Mater Chem B

Alginate-aker injectable composite hydrogels promoted irregular bone regeneration through stem cell recruitment and osteogenic differentiation. [Abstract]

2018 Apr 7;6(13):1951-1964. PMID: 32254361
RSC Adv

A multi-stage computational pipeline and in vitro validation for the discovery of small-molecule translation inhibitors targeting the bacterial ribosome. [Abstract]

2026 Apr 7;16(20):18359-18373. PMID: 41953617
Drug Des Devel Ther

Inhibition of CXCR4 in Spinal Cord and DRG with AMD3100 Attenuates Colon-Bladder Cross-Organ Sensitization. [Abstract]

2022 Jan 6;16:67-81. PMID: 35023903
Cells

Extracellular Vesicles Derived from Bone Marrow in an Early Stage of Ionizing Radiation Damage Are Able to Induce Bystander Responses in the Bone Marrow. [Abstract]

2022 Jan 4;11(1):155. PMID: 35011718
Cells

Tumor Angiogenic Inhibition Triggered Necrosis (TAITN) in Oral Cancer. [Abstract]

2019 Jul 22;8(7):761. PMID: 31336612
ACS Appl Nano Mater

2026 Aug 26;9(35):16874-16884.
Int Immunopharmacol

Apelin-13 regulated thrombotic inflammation and induced homing of EPCs to promote the dissolution and recanalization of deep vein thrombosis. [Abstract]

2026 Jan 15:169:115969. PMID: 41391282
Int Immunopharmacol

Isoferulic acid regulates CXCL12/CXCR4-mediated apoptosis and autophagy in podocyte and mice with STZ-induced diabetic nephropathy. [Abstract]

2025 Jan 10:144:113707. PMID: 39616856
Biomolecules

Impact of SDF-1 and AMD3100 on Hair Follicle Dynamics in a Chronic Stress Model. [Abstract]

2024 Sep 25;14(10):1206. PMID: 39456139
Int J Mol Sci

PIEZO1 Promotes the Migration of Endothelial Cells via Enhancing CXCR4 Expression under Simulated Microgravity. [Abstract]

2024 Jul 1;25(13):7254. PMID: 39000362
Int J Mol Sci

Multiplex Detection of Fluorescent Chemokine Binding to CXC Chemokine Receptors by NanoBRET. [Abstract]

2024 May 4;25(9):5018. PMID: 38732237
Int J Mol Sci

Inhibition of Cxcr4 Disrupts Mouse Embryonic Palatal Mesenchymal Cell Migration and Induces Cleft Palate Occurrence. [Abstract]

2023 Aug 13;24(16):12740. PMID: 37628919
Invest Ophthalmol Vis Sci

CXCR4-Mediated Chemokine Signaling Orchestrates the Progression of Conjunctival Melanocytic Lesions. [Abstract]

2025 Aug 1;66(11):23. PMID: 40778698
Am J Physiol Cell Physiol

Mechanistic insights into SENP1 and OCT4 interaction in promoting drug resistance and stem cell features in colon cancer. [Abstract]

2025 Apr 1;328(4):C1260-C1278. PMID: 40063360
Mol Med Rep

AMD3100 and SDF‑1 regulate cellular functions of endothelial progenitor cells and accelerate endothelial regeneration in a rat carotid artery injury model. [Abstract]

2020 Oct;22(4):3201-3212. PMID: 32945467
Cell Signal

2026 Dec:148:112761. PMID: 42526699
J Cell Mol Med

Stromal Cell Derived Factor-1 Promotes Hepatic Insulin Resistance via Inhibiting Hepatocyte Lipophagy. [Abstract]

2025 Jan;29(2):e70352. PMID: 39855896
Cell Signal

CXCL12-CXCL4 heterodimerization prevents CXCL12-driven breast cancer cell migration. [Abstract]

2020 Feb;66:109488. PMID: 31785332
J Periodontol

Stromal cell-derived factor-1 regulates expression of vascular endothelial growth factor and osteopontin after tooth extraction. [Abstract]

2025 Jul 8. PMID: 40627767
ACS Infect Dis

Bcl-2 Antagonist Obatoclax Reactivates Latent HIV-1 via the NF-κB Pathway and Induces Latent Reservoir Cell Apoptosis in Latently Infected Cells. [Abstract]

2023 Nov 10;9(11):2105-2118. PMID: 37796279
Transl Stroke Res

SDF-1α/CXCR4 Pathway Mediates Hemodynamics-Induced Formation of Intracranial Aneurysm by Modulating the Phenotypic Transformation of Vascular Smooth Muscle Cells. [Abstract]

2022 Apr;13(2):276-286. PMID: 34173205
Curr Issues Mol Biol

2026 Jul 17;48(7):730. PMID: 42510970
Cell Transplant

Effects of Low-Intensity Pulsed Ultrasound on the Migration and Homing of Human Amnion-Derived Mesenchymal Stem Cells to Ovaries in Rats With Premature Ovarian Insufficiency. [Abstract]

2022 Jan-Dec;31:9636897221129171. PMID: 36282038
Br J Haematol

CXCR4 antagonists disrupt leukaemia-meningeal cell adhesion and attenuate chemoresistance. [Abstract]

2023 May;201(3):459-469. PMID: 36535585
Stem Cells Int

IL-1 β Pretreatment Improves the Efficacy of Mesenchymal Stem Cells on Acute Liver Failure by Enhancing CXCR4 Expression. [Abstract]

2020 Jul 7:2020:1498315. PMID: 32724311
Andrology

Saxagliptin alleviates erectile dysfunction through increasing stromal cell-derived factor-1 in diabetes mellitus. [Abstract]

2023 Feb;11(2):295-306. PMID: 36113503
J Diabetes Complications

Plerixafor stimulates adhesive activity and endothelial regeneration of endothelial progenitor cells via elevating CXCR7 expression. [Abstract]

2020 Oct;34(10):107654. PMID: 32741660
Kaohsiung J Med Sci

MiR-32-5p promoted epithelial-to-mesenchymal transition of oral squamous cell carcinoma cells via regulating the KLF2/CXCR4 pathway. [Abstract]

2022 Feb;38(2):120-128. PMID: 34741382
J Steroid Biochem Mol Biol

The ERβ-CXCL19/CXCR4-NFκB pathway is critical in mediating the E2-induced inflammation response in the orange-spotted grouper (Epinephelus coioides). [Abstract]

2021 Sep:212:105926. PMID: 34091027
Cell Tissue Res

M2 macrophages promote vasculogenesis during retinal neovascularization by regulating bone marrow-derived cells via SDF-1/VEGF. [Abstract]

2020 Jun;380(3):469-486. PMID: 31989253
Brain Behav

Repetitive Transcranial Magnetic Stimulation Improves Cognitive Impairment via the Regulation of White Matter Injury in Rats With Ischemic Stroke. [Abstract]

2025 Dec;15(12):e71117. PMID: 41355332
PLoS One

CXCR4 inhibition with AMD3100 attenuates amphetamine induced locomotor activity in adolescent Long Evans male rats. [Abstract]

2021 Mar 1;16(3):e0247707. PMID: 33647040
Virology

Generation and evaluation of an EcoHIV mouse model to study HIV-1 integration and expression. [Abstract]

2026 Jun 4:623:110991. PMID: 42320113
Biochem Biophys Res Commun

Assessing the effect and related mechanism of naringenin on the proliferation, osteogenic differentiation and endothelial differentiation of human periodontal ligament stem cells. [Abstract]

2021 Jan 1:534:337-342. PMID: 33250176
Cell Physiol Biochem

MicroRNA-381 Favors Repair of Nerve Injury Through Regulation of the SDF-1/CXCR4 Signaling Pathway via LRRC4 in Acute Cerebral Ischemia after Cerebral Lymphatic Blockage. [Abstract]

2018;46(3):890-906. PMID: 29669322

Plerixafor purchased from MedChemExpress. Usage Cited in: Cell Physiol Biochem. 2018;46(3):890-906. [Abstract]

The protein expression of LRRC4, SDF-1, CXCR4, ERK, Slit2 and VEGF in the brain tissue of rats is determined by Western blotting.
Exp Ther Med

Repetitive transcranial magnetic stimulation increases neurological function and endogenous neural stem cell migration via the SDF-1α/CXCR4 axis after cerebral infarction in rats. [Abstract]

2021 Sep;22(3):1037. PMID: 34373723
Oncol Lett

Targeting CXC motif chemokine receptor 4 inhibits the proliferation, migration and angiogenesis of lung cancer cells. [Abstract]

2018 Sep;16(3):3976-3982. PMID: 30128017
Anticancer Drugs

CXCR4 blockade with AMD3100 enhances Taxol chemotherapy to limit ovarian cancer cell growth. [Abstract]

2017 Oct;28(9):935-942. PMID: 28817386
SSRN

2026 Sep 5.
bioRxiv

Dietary fructose promotes MASH/HCC progression through enhanced intestinal HIF-2α-dependent iron absorption. [Abstract]

2026 Jun 11:2026.06.07.729655. PMID: 42327230
bioRxiv

2026 Jun 14.
University of Pittsburgh

2026.
Res Sq

Cellular context and ligand class shape CXCR4-CCR5 heteromerization in live cells. [Abstract]

2026 May 20:rs.3.rs-9499667. PMID: 42239782
Res Sq

2026 Feb 2.
Preprints

2026 Mar 23.
bioRxiv

2025 Oct 7.
Res Sq

2025 Aug 07.
Res Sq

2025 Mar 16.
SSRN

2025 Jan 13.
University of Zagreb

2024 May 23.
Research Square Preprint

2023 Oct 23.
Ruprecht-Karls-University Heidelberg

2023 Aug 3.
Research Square Preprint

2022 Jul.
Uppsala University

2022 Feb.
SSRN

5 Feb 2022.
Stem Cell Res Ther

Important role of the SDF-1/CXCR4 axis in the homing of systemically transplanted human amnion-derived mesenchymal stem cells (hAD-MSCs) to ovaries in rats with chemotherapy-induced premature ovarian insufficiency (POI). [Abstract]

2022 Feb 23;13(1):79. PMID: 35197118
J Oncol

Exosomes Derived from RM-1 Cells Promote the Recruitment of MDSCs into Tumor Microenvironment by Upregulating CXCR4 via TLR2/NF- κ B Pathway. [Abstract]

2021 Oct 8:2021:5584406. PMID: 34659412
Oxid Med Cell Longev

Recombinant High-Mobility Group Box 1 (rHMGB1) Promotes NRF2-Independent Mitochondrial Fusion through CXCR4/PSMB5-Mediated Drp1 Degradation in Endothelial Cells. [Abstract]

2021 Aug 2;2021:9993240. PMID: 34394840
Research Square Preprint

2021 Aug.
Universität Hamburg

2021 Mar 19.
Patent

US20200360478A1.
Biomed Pharmacother

Bone marrow mesenchymal stem cells in microenvironment transform into cancer-associated fibroblasts to promote the progression of B-cell acute lymphoblastic leukemia. [Abstract]

2020 Oct:130:110610. PMID: 34321159
Patent

US20190133998A1.
University of Munich

2019 Apr.
BMC Complement Altern Med

Baicalin promotes apoptosis and inhibits proliferation and migration of hypoxia-induced pulmonary artery smooth muscle cells by up-regulating A2a receptor via the SDF-1/CXCR4 signaling pathway. [Abstract]

2018 Dec 12;18(1):330. PMID: 30541517
Chinese Journal of Tissue Engineering Research

2014,18(45): 7327-7332.

Lösungsmittel & Löslichkeit

In Vitro:

Ethanol : 50 mg/mL (99.45 mM; Need ultrasonic)

DMSO : 1.92 mg/mL (3.82 mM; ultrasonic and warming and adjust pH to 7 with 1 M HCL and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.9889 mL

9.9447 mL

19.8894 mL

5 mM

0.3978 mL

1.9889 mL

3.9779 mL

10 mM

0.1989 mL

0.9945 mL

1.9889 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.97 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (4.97 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.97 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (312 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Wuchter P, et al. Plerixafor induces the rapid and transient release of stromal cell-derived factor-1 alpha from human mesenchymal stromal cells and influences the migration behavior of human hematopoietic progenitor cells. Cell and tissue research. 2014 Feb;355(2):315-26.

[2]. Aftab Ullah, et al. (2019) CXCR4-targeted liposomal mediated co-delivery of pirfenidone and AMD3100 for the treatment of TGFβ-induced HSC-T6 cells activation, International Journal of Nanomedicine, 2927-2944.

[3]. Meeson R, et al. VEGF with AMD3100 endogenously mobilizes mesenchymal stem cells and improves fracture healing. J Orthop Res. 2019 Jun;37(6):1294-1302.

[4]. Saiman Y, et al. Inhibition of the CXCL12/CXCR4 chemokine axis with AMD3100, a CXCR4 small molecule inhibitor, worsens murine hepatic injury. Hepatology research : the official journal of the Japan Society of Hepatology. 2015 Jul;45(7):794-803.

[5]. Qixian Sun, et al. (2022) C-X-C-Chemokine-Receptor-Type-4
Inhibitor AMD3100 Attenuates Pulmonary Inflammation and Fibrosis in Silicotic Mice, Journal
of Inflammation Research, 5827-5843.

[6]. Peng LH, et al. Effects of AMD3100 subconjunctival injection on alkali burn induced corneal neovascularization in mice. International journal of ophthalmology. 2011;4(1):44-8.

[7]. Li JK, et al. Inhibition of CXCR4 activity with AMD3100 decreases invasion of human colorectal cancer cells in vitro. World journal of gastroenterology. 2008 Apr 21;14(15):2308-13.

[8]. Lakhanpal T, et al. Bifunctional chelator-plerixafor complex for targeting CXCR4 receptors: radiolabeling, in-vitro, and preclinical study. Nucl Med Commun. 2025 Aug 1;46(8):726-737.

[9]. Zhang F, et al. CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy. Biomacromolecules. 2017 Jun 12;18(6):1793-1802.

[10]. Li Z, et al. AMD3100 Accelerates Reendothelialization of Neointima in Rabbit Saccular Aneurysm After Flow Diverter Treatment. World Neurosurg. 2017 Nov;107:416-423.

[11]. Poty S, et al. New AMD3100 derivatives for CXCR4 chemokine receptor targeted molecular imaging studies: synthesis, anti-HIV-1 evaluation and binding affinities. Dalton transactions (Cambridge, England : 2003). 2015 Mar 21;44(11):5004-16.

[12]. Huang J, et al. CXCR4 antagonist AMD3100 protects blood-brain barrier integrity and reduces inflammatory response after focal ischemia in mice. Stroke. 2013 Jan;44(1):190-7.

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / Ethanol	1 mM	1.9889 mL	9.9447 mL	19.8894 mL	49.7235 mL
Ethanol	5 mM	0.3978 mL	1.9889 mL	3.9779 mL	9.9447 mL
	10 mM	0.1989 mL	0.9945 mL	1.9889 mL	4.9724 mL
	15 mM	0.1326 mL	0.6630 mL	1.3260 mL	3.3149 mL
	20 mM	0.0994 mL	0.4972 mL	0.9945 mL	2.4862 mL
	25 mM	0.0796 mL	0.3978 mL	0.7956 mL	1.9889 mL
	30 mM	0.0663 mL	0.3315 mL	0.6630 mL	1.6575 mL
	40 mM	0.0497 mL	0.2486 mL	0.4972 mL	1.2431 mL
	50 mM	0.0398 mL	0.1989 mL	0.3978 mL	0.9945 mL
	60 mM	0.0331 mL	0.1657 mL	0.3315 mL	0.8287 mL
	80 mM	0.0249 mL	0.1243 mL	0.2486 mL	0.6215 mL

Bioz

Plerixafor

120 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Plerixafor

Publications Citing Use of MedChemExpress (MCE) Plerixafor

Alle CXCR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Beschreibung

IC₅₀ & Target

Cellular Effect

In Vitro

In Vivo

Clinical Trial

Chemical Information

Publications (120)

Lösungsmittel & Löslichkeit

In Vitro:

In Vivo:

In Vivo Dissolution Calculator

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Keywords

Your Recently Viewed Products

Plerixafor

Publications Citing Use of MedChemExpress (MCE) Plerixafor

Alle CXCR Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Beschreibung

IC50 & Target

Cellular Effect

In Vitro

In Vivo

Clinical Trial

Chemical Information

Publications (120)

Lösungsmittel & Löslichkeit

In Vitro:

In Vivo:

In Vivo Dissolution Calculator

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Plerixafor Related Classifications

HY-10046 Related Classifications

Bioz

Keywords

Your Recently Viewed Products

IC₅₀ & Target